2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one

• ChemBase ID: 4411
• Molecular Formular: C14H18N2O
• Molecular Mass: 230.30552
• Monoisotopic Mass: 230.14191321
• SMILES: O=C(c1c(nn2c1cccc2)C(C)C)C(C)C
• Canonical SMILES: CC(C(=O)c1c(nn2c1cccc2)C(C)C)C
• InChI: InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3
• InChIKey: ZJVFLBOZORBYFE-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
• IUPAC Traditional name: ketas; ibudilast; 2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one
• Synonyms: MN-166; AV-411; 2-Isopropyl-3-isobutyrylpyrazolo(1,5-a)pyridine; 3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine; 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine; Eyevinal; I0157_SIGMA; Ibudilast (jan/inn); Ibudilast [inn:jan]; Ibudilastum; Ibudilastum [latin]; Ke tas; Ketas; Ketas (TN); Lopac-I-0157; Pyrazolo(1,5-a)pyridine, 3-isobutyryl-2-isopropyl-; Tocris-1694; UNII-M0TTH61XC5; Ibudilast; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl] 1-propanone; KC-404; Ibudilast; 2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone; 1-(2-Isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one; 2-Isopropyl-3-isobutyrylpyrazolo[1,5-a]pyridine; AV 411; KC 404

Database IDs

• CAS Number: 50847-11-5
• MDL Number: MFCD00864808
• PubChem SID: 160967843; 99443231; 24278482
• PubChem CID: 3671

CALCULATED PROPERTIES

JChem

• Acid pKa: 16.124111
• H Acceptors: 2
• H Donor: 0
• LogD (pH = 5.5): 3.6791465
• LogD (pH = 7.4): 3.6792438
• Log P: 3.679245
• Molar Refractivity: 79.375 cm^3
• Polarizability: 26.83163 Å^3
• Polar Surface Area: 34.37 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

ALOGPS 2.1

• Log P: 3.36
• LOG S: -3.11
• Solubility (Water): 1.79e-01 g/l

PROPERTIES

Physical Property

• Solubility: Chloroform; Dichloromethane; DMSO: soluble28 mg/mL; Ether; H2O: soluble4.5 mg/mL; Hexane,
• Apperance: white solid; White Solid
• Melting Point: 43-46°C

Safety Information

• Storage Condition: -20°C Freezer
• RTECS: UR0711200
• European Hazard Symbols: Harmful (Xn)
• German water hazard class: 3
• Risk Statements: 22-36/37/38
• Safety Statements: 26-36
• GHS Pictograms: GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H315-H319-H335
• GHS Precautionary statements: P261-P305 + P351 + P338
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• Storage Temperature: 2-8°C

Pharmacology Properties

• Gene Information: human ... PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144)
• Mechanism of Action: Bronchodilator; Lowers Ca 2+ deposition in soft tissues; Phosphodiesterase inhibitor; Vasodilator

Product Information

• Purity: ≥99% (HPLC)
• Application(s): Antiallergic; Bronchodilator; Cerebral vasodilator; Neuroprotective
• Empirical Formula (Hill Notation): C14 H18 N2 O

DETAILS

DrugBank - DB05266

• Drug Groups: approved; investigational
• Description: Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.
• Indication: For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.
• Toxicity: Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia
• Affected Organisms: Humans and other mammals
• Half Life: 19 hours
• External Links: Wikipedia

Sigma Aldrich - I0157

Biochem/physiol Actions
Phosphodiesterase IV (PDE4) inhbitor. Inhibits platelet aggregation. Anti-asthma drug.

Toronto Research Chemicals - I125000

A leukotriene D4 antagonist. Used as an antiallergic, antiasthmatic, and vasodilator (cerebral).

REFERENCES

• Nishino, K., et al.: Japan J. Pharmacol., 33, 267 (1983)
• Ohashi, M., et al.: Arch. Int. Pharmacodyn., 280, 216 (1983)
• Armstead, W.M., et al.: J. Pharmacol., Exp. Ther., 244, 138 (1983)
• Ger. Pat., 1973, Kyorin Pharm, 2 315 801; CA, 80, 14923s, (synth)
• Japan. Pat., 1977, Kyorin Pharm, 77 14 799; CA, 87, 53282w, (synth, pharmacol)
• Nagai, H. et al., Jpn. J. Pharmacol., 1983, 33, 1215, (pharmacol)
• Mue, S. et al., Arch. Int. Pharmacodyn. Ther., 1986, 283, 153, (pharmacol)
• Izumi, Y. et al., Arzneim.-Forsch., 1990, 40, 1300
• Yasui, M. et al., J. Int. Med. Res., 1990, 18, 415, (pharmacol)
• Ohashi, M. et al., Int. Arch. Allergy Appl. Immunol., 1993, 101, 288, (pharmacol)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 1140
• Souness, J.E. et al., Br. J. Pharmacol., 1994, 111, 1081, (pharmacol)